Inhibition of activated phosphatidylinositol 3-kinase/AKT pathway in malignant pleural mesothelioma leads to G1 cell cycle arrest

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1677-1681

  Mikami, Iwao ^a,c   Zhang, Fang ^a   Hirata, Tomomi ^a,c   Okamoto, Junichi ^a,c   Koizumi, Kiyoshi ^c   Shimizu, Kazuo ^c   Jablons, David ^a,b   He, Biao ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

AKT; G1 arrest; Human; Mesothelioma; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; G1 PHASE; HUMANS; MESOTHELIOMA; MORPHOLINES; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PLEURAL NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 78649412235     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001033     Document Type: Article

References (26)

1. Belli C, Fennell D, Giovannini M, Gaudino G and Mutti L: Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14: 423-437, 2009.
2. Yang CT, You L, Uematsu K, Yeh CC, McCormick F and Jablons DM: p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 61: 5959-5963, 2001.
3. Price B: Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145: 211-218, 1997. (Pubitemid 27057172)
4. Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999.
5. Tomasetti M, Amati M, Santarelli L, Alleva R and Neuzil J: Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2: 190-206, 2009.
6. Sekido Y: Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 101: 1-6, 2010.
7. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB and Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089, 2005.
8. Janne PA, Taffaro ML, Salgia R and Johnson BE: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242-5247, 2002. (Pubitemid 35024597)
9. Nutt JE, O'Toole K, Gonzalez D and Lunec J: Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. Eur J Cancer 45: 1684-1691, 2009.
10. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D and Kratzke RA: Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 64: 7479-7485, 2004.
11. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86, 2005.
12. Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res 26: 809-821, 2006.
13. Lee J and Kim SS: The function of p27 KIP1 during tumor development. Exp Mol Med 41: 765-771, 2009.
14. Beer TW, Sheperd P and Pullinger NC: p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 38: 535-541, 2001.
15. Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, Ivaldi C, Chiusa L and Bussolati G: p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 92: 1245-1250, 2001.
16. Viglietto G, Motti ML and Fusco A: Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1: 394-400, 2002.
17. Slingerland J: Transforming growth factor-beta and breast cancer: introduction. Breast Cancer Res 2: 91, 2000.
18. Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
19. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
20. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002.
21. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
22. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
23. Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511, 1998. (Pubitemid 28553242)
24. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A and Pagano M: Ubiquitination of p27kip1 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13: 1181-1189, 1999.
25. Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27Kip1. Nat Cell Biol 1: 193-199, 1999.
26. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27Kip1. Science 269: 682-685, 1995.